Eupraxia Pharmaceuticals (EPRXF) Stock Price, News & Analysis

Company Overview

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Key Stats

• Today's Range: C$2.76 to C$3.07
• 50-Day Range: C$2.36 to C$3.60
• 52-Week Range: C$2.93 to C$6.78
• Volume: 7,778 shs
• Average Volume: 7,410 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EPRXF Stock Analysis - Frequently Asked Questions

How have EPRXF shares performed this year?

Eupraxia Pharmaceuticals' stock was trading at C$4.16 at the start of the year. Since then, EPRXF stock has decreased by 28.1% and is now trading at C$2.99.
View the best growth stocks for 2024 here.

How do I buy shares of Eupraxia Pharmaceuticals?

Shares of EPRXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EPRXF
• CUSIP: N/A
• CIK: N/A
• Web: www.eupraxiapharma.com
• Phone: 250 590 3968
• Fax: N/A
• Employees: 21
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A